Neuroblastoma Research and Treatments

The paper identifies PAK2-mediated phosphorylation of MYCN and MAX as a tumor-suppressor mechanism in neuroblastoma, with potential therapeutic strategies to restore its activity.

This study identifies 13.9% of neuroblastoma patients with pathogenic germline variants in cancer predisposition genes, associated with worse survival and enriched in DNA repair genes like BARD1.

The paper identifies a transcriptional signature distinguishing low- and high-risk neuroblastomas and shows that NXPH1/-NRXN signaling inhibits metastasis while promoting tumor growth.